Annual Accounts Payable
$4.33 M
+$1.19 M+37.83%
31 December 2023
Summary:
GT Biopharma annual accounts payable is currently $4.33 million, with the most recent change of +$1.19 million (+37.83%) on 31 December 2023. During the last 3 years, it has risen by +$2.08 million (+92.96%). GTBP annual accounts payable is now -47.15% below its all-time high of $8.19 million, reached on 31 December 2021.GTBP Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$2.61 M
+$895.00 K+52.13%
30 September 2024
Summary:
GT Biopharma quarterly accounts payable is currently $2.61 million, with the most recent change of +$895.00 thousand (+52.13%) on 30 September 2024. Over the past year, it has dropped by -$1.36 million (-34.21%). GTBP quarterly accounts payable is now -68.10% below its all-time high of $8.19 million, reached on 31 December 2021.GTBP Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GTBP Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +37.8% | -34.2% |
| 3 y3 years | +93.0% | -6.8% |
| 5 y5 years | +145.6% | +51.9% |
GTBP Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -47.1% | +93.0% | -68.1% | +52.1% |
| 5 y | 5 years | -47.1% | +145.6% | -68.1% | +74.5% |
| alltime | all time | -47.1% | +1342.7% | -68.1% | +920.3% |
GT Biopharma Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $2.61 M(+52.1%) |
| June 2024 | - | $1.72 M(-46.6%) |
| Mar 2024 | - | $3.21 M(-25.8%) |
| Dec 2023 | $4.33 M(+37.8%) | $4.33 M(+9.0%) |
| Sept 2023 | - | $3.97 M(+13.4%) |
| June 2023 | - | $3.50 M(+11.8%) |
| Mar 2023 | - | $3.13 M(-0.3%) |
| Dec 2022 | $3.14 M(-61.7%) | $3.14 M(-5.6%) |
| Sept 2022 | - | $3.33 M(-54.2%) |
| June 2022 | - | $7.26 M(-10.5%) |
| Mar 2022 | - | $8.11 M(-0.9%) |
| Dec 2021 | $8.19 M(+265.1%) | $8.19 M(+192.3%) |
| Sept 2021 | - | $2.80 M(+87.2%) |
| June 2021 | - | $1.50 M(-37.0%) |
| Mar 2021 | - | $2.38 M(+6.0%) |
| Dec 2020 | $2.24 M(+15.6%) | $2.24 M(+3.3%) |
| Sept 2020 | - | $2.17 M(+8.5%) |
| June 2020 | - | $2.00 M(-15.6%) |
| Mar 2020 | - | $2.37 M(+22.2%) |
| Dec 2019 | $1.94 M(+10.1%) | $1.94 M(+12.8%) |
| Sept 2019 | - | $1.72 M(+0.6%) |
| June 2019 | - | $1.71 M(-9.9%) |
| Mar 2019 | - | $1.90 M(+7.7%) |
| Dec 2018 | $1.76 M(-30.8%) | $1.76 M(-21.7%) |
| Sept 2018 | - | $2.25 M(+19.3%) |
| June 2018 | - | $1.89 M(+3.1%) |
| Mar 2018 | - | $1.83 M(-28.1%) |
| Dec 2017 | $2.55 M(+21.2%) | $2.55 M(-6.2%) |
| Sept 2017 | - | $2.71 M(+15.6%) |
| June 2017 | - | $2.35 M(+13.9%) |
| Mar 2017 | - | $2.06 M(-1.9%) |
| Dec 2016 | $2.10 M(+135.2%) | $2.10 M(+15.8%) |
| Sept 2016 | - | $1.81 M(+15.2%) |
| June 2016 | - | $1.57 M(+2.3%) |
| Mar 2016 | - | $1.54 M(+72.2%) |
| Dec 2015 | $893.00 K(+116.7%) | $893.00 K(-7.7%) |
| Sept 2015 | - | $968.00 K(+124.6%) |
| June 2015 | - | $431.00 K(+68.4%) |
| Mar 2015 | - | $256.00 K(-37.9%) |
| Dec 2014 | $412.00 K(-56.2%) | $412.00 K(-49.8%) |
| Sept 2014 | - | $820.00 K(-11.4%) |
| June 2014 | - | $925.00 K(-1.1%) |
| Mar 2014 | - | $935.00 K(-0.5%) |
| Dec 2013 | $940.00 K(+7.1%) | $940.00 K(+0.5%) |
| Sept 2013 | - | $935.00 K(+3.4%) |
| June 2013 | - | $904.00 K(+2.4%) |
| Mar 2013 | - | $883.00 K(+0.6%) |
| Dec 2012 | $878.00 K(+8.9%) | $878.00 K(+2.3%) |
| Sept 2012 | - | $858.00 K(+5.5%) |
| June 2012 | - | $813.00 K(-0.2%) |
| Mar 2012 | - | $815.00 K(+1.1%) |
| Dec 2011 | $806.00 K(+29.0%) | $806.00 K(-17.2%) |
| Sept 2011 | - | $974.00 K(+26.2%) |
| June 2011 | - | $772.00 K(-9.8%) |
| Mar 2011 | - | $856.00 K(+37.0%) |
| Dec 2010 | $625.00 K(-32.4%) | $625.00 K(+0.2%) |
| Sept 2010 | - | $624.00 K(-23.0%) |
| June 2010 | - | $810.00 K(+4.0%) |
| Mar 2010 | - | $779.00 K(-15.8%) |
| Dec 2009 | $925.00 K | $925.00 K(-6.5%) |
| Sept 2009 | - | $989.00 K(+3.3%) |
| June 2009 | - | $957.00 K(-1.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2009 | - | $967.00 K(+5.2%) |
| Dec 2008 | $919.00 K(-11.1%) | $919.00 K(-4.2%) |
| Sept 2008 | - | $959.00 K(-28.6%) |
| June 2008 | - | $1.34 M(+11.2%) |
| Mar 2008 | - | $1.21 M(+16.8%) |
| Dec 2007 | $1.03 M(+35.5%) | $1.03 M(+5.8%) |
| Sept 2007 | - | $977.00 K(+2.3%) |
| June 2007 | - | $955.00 K(-1.8%) |
| Mar 2007 | - | $973.00 K(+27.5%) |
| Dec 2006 | $763.00 K(+9.2%) | $763.00 K(-19.5%) |
| Sept 2006 | - | $948.00 K(+4.5%) |
| June 2006 | - | $907.00 K(+5.7%) |
| Mar 2006 | - | $858.00 K(+22.7%) |
| Dec 2005 | $699.00 K(+42.4%) | $699.00 K(+109.3%) |
| Sept 2005 | - | $334.00 K(-16.3%) |
| June 2005 | - | $399.00 K(+0.8%) |
| Mar 2005 | - | $396.00 K(-19.3%) |
| Dec 2004 | $491.00 K(-19.4%) | $491.00 K(-8.4%) |
| Sept 2004 | - | $536.00 K(-15.7%) |
| June 2004 | - | $636.00 K(+18.0%) |
| Mar 2004 | - | $539.00 K(-11.5%) |
| Dec 2003 | $609.00 K(+89.7%) | $609.00 K(+39.7%) |
| Sept 2003 | - | $436.00 K(-24.2%) |
| June 2003 | - | $575.00 K(+46.7%) |
| Mar 2003 | - | $392.00 K(+22.1%) |
| Dec 2002 | $321.00 K(-45.5%) | $321.00 K(+5.2%) |
| Sept 2002 | - | $305.00 K(-37.2%) |
| June 2002 | - | $486.00 K(+0.2%) |
| Mar 2002 | - | $485.00 K(-17.7%) |
| Dec 2001 | $589.00 K(-6.2%) | $589.00 K(-5.3%) |
| Sept 2001 | - | $622.00 K(-11.0%) |
| June 2001 | - | $699.00 K(+35.2%) |
| Mar 2001 | - | $517.00 K(-17.7%) |
| Dec 2000 | $628.00 K(-44.5%) | $628.00 K(+11.9%) |
| Sept 2000 | - | $561.00 K(+17.1%) |
| June 2000 | - | $479.00 K(+3.7%) |
| Mar 2000 | - | $462.00 K(-59.2%) |
| Dec 1999 | $1.13 M(+61.6%) | $1.13 M(+41.4%) |
| Sept 1999 | - | $800.00 K(+33.3%) |
| June 1999 | - | $600.00 K(0.0%) |
| Mar 1999 | - | $600.00 K(-14.3%) |
| Dec 1998 | $700.00 K(-56.3%) | $700.00 K(-22.2%) |
| Sept 1998 | - | $900.00 K(0.0%) |
| June 1998 | - | $900.00 K(-30.8%) |
| Mar 1998 | - | $1.30 M(-18.8%) |
| Dec 1997 | $1.60 M(+14.3%) | $1.60 M(+23.1%) |
| Sept 1997 | - | $1.30 M(+62.5%) |
| June 1997 | - | $800.00 K(-61.9%) |
| Mar 1997 | - | $2.10 M(+50.0%) |
| Dec 1996 | $1.40 M(+16.7%) | $1.40 M(-12.5%) |
| Sept 1996 | - | $1.60 M(+77.8%) |
| June 1996 | - | $900.00 K(-47.1%) |
| Mar 1996 | - | $1.70 M(+41.7%) |
| Dec 1995 | $1.20 M(-25.0%) | $1.20 M(0.0%) |
| Sept 1995 | - | $1.20 M(+9.1%) |
| June 1995 | - | $1.10 M(-47.6%) |
| Mar 1995 | - | $2.10 M(+31.3%) |
| Dec 1994 | $1.60 M(+433.3%) | $1.60 M(+23.1%) |
| Sept 1994 | - | $1.30 M(+85.7%) |
| June 1994 | - | $700.00 K(+75.0%) |
| Mar 1994 | - | $400.00 K(+33.3%) |
| Dec 1993 | $300.00 K | $300.00 K |
FAQ
- What is GT Biopharma annual accounts payable?
- What is the all time high annual accounts payable for GT Biopharma?
- What is GT Biopharma annual accounts payable year-on-year change?
- What is GT Biopharma quarterly accounts payable?
- What is the all time high quarterly accounts payable for GT Biopharma?
- What is GT Biopharma quarterly accounts payable year-on-year change?
What is GT Biopharma annual accounts payable?
The current annual accounts payable of GTBP is $4.33 M
What is the all time high annual accounts payable for GT Biopharma?
GT Biopharma all-time high annual accounts payable is $8.19 M
What is GT Biopharma annual accounts payable year-on-year change?
Over the past year, GTBP annual accounts payable has changed by +$1.19 M (+37.83%)
What is GT Biopharma quarterly accounts payable?
The current quarterly accounts payable of GTBP is $2.61 M
What is the all time high quarterly accounts payable for GT Biopharma?
GT Biopharma all-time high quarterly accounts payable is $8.19 M
What is GT Biopharma quarterly accounts payable year-on-year change?
Over the past year, GTBP quarterly accounts payable has changed by -$1.36 M (-34.21%)